Загрузка...
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food and Drug Administration (FDA) in January 2010 to improve walking in people with multiple sclerosis, as determine...
Сохранить в:
| Опубликовано в: : | Drug Healthc Patient Saf |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4687626/ https://ncbi.nlm.nih.gov/pubmed/26719727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S97113 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|